Capital Market Strategies LLC Makes New $461,000 Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Market Strategies LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,715 shares of the company’s stock, valued at approximately $461,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. lifted its holdings in CRISPR Therapeutics by 4.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after buying an additional 211 shares in the last quarter. Boston Family Office LLC raised its position in shares of CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC boosted its stake in shares of CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after buying an additional 218 shares during the last quarter. National Bank of Canada FI grew its position in shares of CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after buying an additional 231 shares during the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock valued at $2,744,179 in the last quarter. Insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Chardan Capital reiterated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus price target of $77.93.

CRISPR Therapeutics Stock Up 6.5 %

CRSP stock traded up $2.68 during trading on Monday, reaching $43.70. 1,419,041 shares of the company’s stock were exchanged, compared to its average volume of 1,497,464. The firm has a market cap of $3.73 billion, a PE ratio of -15.44 and a beta of 1.68. The company’s fifty day moving average price is $46.92 and its 200-day moving average price is $49.24. CRISPR Therapeutics AG has a 1-year low of $38.20 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the firm posted ($1.41) earnings per share. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.